Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05327946 · ClinicalTrials.gov registry record · Phase 1

A Study in People With Advanced Cancer to Test How Well Different Doses of BI 770371 Alone or in Combination With Ezabenlimab Are Tolerated

A Phase 1 study of Solid Tumors, sponsored by Boehringer Ingelheim.

Active
Registry status
Phase 1
Development phase
36
Enrollment target
5
Study locations

NCT05327946 is a Phase 1 study of Solid Tumors that is active but no longer recruiting, run by Boehringer Ingelheim. The registered enrollment target is 36 participants, below the 284-participant average among 125 other Solid Tumors trials with a reported enrollment target (87% lower). The trial reports 5 study locations across 4 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05327946, a Phase 1 study of Solid Tumors, is active but no longer recruiting, sponsored by Boehringer Ingelheim.

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
36 participants
Enrollment target
5
Study locations

Study Summary

This study is open to adults with advanced cancer (solid tumours). People for whom previous treatment was not successful and for whom no other treatment options exist can join the study. The purpose of this study is to find the highest dose of BI 770371 that people with advanced cancer can tolerate when taken alone or together with a medicine called ezabenlimab. BI 770371 and ezabenlimab are antibodies that may help the immune system fight cancer (checkpoint inhibitors). In this study, BI 770371 is given to people for the first time. Participants get BI 770371 alone or together with ezabenlimab as an infusion every 3 weeks. It is planned that participants can stay in the study for up to 2 years, if they benefit from treatment and can tolerate it. During this time, they visit the study site regularly. The doctors collect information on any health problems of the participants. The doctors also regularly monitor the size of the tumour.

Conditions Studied

Solid Tumors

Interventions

  • DRUG BI 770371
  • DRUG ezabenlimab

Study Locations (5)

Other

  • National Cancer Center Hospital East - Chiba, Kashiwa
  • National Cancer Center Hospital - Tokyo, Chuo-ku

Florida

  • Florida Cancer Specialists-Sarasota-61670 - Sarasota

New Jersey

  • John Theurer Cancer Center - Hackensack

Quebec

  • Centre Hospitalier de l'Universite de Montreal (CHUM) - Montreal

Trial Details

FieldValue
Enrollment Target 36 participants
Start Date 2022-05-17
Est. Completion 2026-09-30
Phase Phase 1

Sponsor

Boehringer Ingelheim

515 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05327946

The ClinicalTrials.gov registry entry for NCT05327946 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 284-participant average among 125 other Solid Tumors trials with a reported enrollment target (87% lower). The listed sponsor is Boehringer Ingelheim, which has 515 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Solid Tumors appearing as the primary indexed condition, and to 2 interventions - of which BI 770371 is the first listed.

NCT05327946 reports 5 study locations spanning 4 distinct geographic areas - top geographies include Other, Florida, New Jersey.

Frequently Asked Questions

What is clinical trial NCT05327946 about?

NCT05327946 is a clinical study titled "A Study in People With Advanced Cancer to Test How Well Different Doses of BI 770371 Alone or in Combination With Ezabenlimab Are Tolerated". This study is open to adults with advanced cancer (solid tumours). People for whom previous treatment was not successful and for whom no other treatment options exist can join the study. The purpose of this study is to find the highest dose of BI 770371 that people with advanced cancer can tolerate...

What is the current status of trial NCT05327946?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 36 participants. The study started on 2022-05-17. Estimated completion is 2026-09-30.

What conditions does trial NCT05327946 study?

This clinical trial studies the following conditions: Solid Tumors.

What interventions are being tested in trial NCT05327946?

The interventions under investigation include: BI 770371 (DRUG), ezabenlimab (DRUG).

Who is sponsoring clinical trial NCT05327946?

This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05327946 being conducted?

This trial has 5 study locations across Florida, New Jersey, Quebec. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Solid Tumors

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Solid Tumors

All registered trials for this condition

Florida

All trials with a study site in Florida

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.